Alaunos Therapeutics (TCRT) Non Operating Income (2020 - 2025)
Alaunos Therapeutics' (TCRT) quarterly Non Operating Income came in at $14000.0 in Q4 2025, up 7.69% YoY from $13000.0 in Q4 2024, and down 50.0% on a QoQ basis from $28000.0 in Q3 2025.
Alaunos Therapeutics (TCRT) Non Operating Income (2020 - 2025) Analysis & Trends
Alaunos Therapeutics (TCRT) has 6 years of Non Operating Income data on file, last reported at $14000.0 in Q4 2025.
- Quarterly Non Operating Income rose 7.69% year-over-year to $14000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $49000.0 (down 63.16% YoY) and the FY2025 annual result came in at $49000.0, down 63.16% from the prior year.
- Non Operating Income eased to $14000.0 in Q4 2025, from $28000.0 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $188000.0 in Q3 2023 to a low of -$791000.0 in Q2 2023.
- A 5-year average of -$226000.0 and a median of -$1500.0 in 2021 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2022 — Non Operating Income tumbled 7911.11% — and 2023, when it jumped 132.03%.
- Tracing TCRT's Non Operating Income over 5 years: stood at -$743000.0 in 2021, then grew by 14.13% to -$638000.0 in 2022, then surged by 116.61% to $106000.0 in 2023, then plunged by 87.74% to $13000.0 in 2024, then rose by 7.69% to $14000.0 in 2025.
- The last three Non Operating Income figures came in at $14000.0 (Q4 2025), $28000.0 (Q3 2025), and -$12000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Alaunos Therapeutics | 4.28 Mn | 4.16 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 14,000.00 |
| Sep 30, 2025 | 28,000.00 |
| Jun 30, 2025 | -12,000.00 |
| Mar 31, 2025 | 19,000.00 |
| Dec 31, 2024 | 13,000.00 |
| Sep 30, 2024 | 23,000.00 |
| Jun 30, 2024 | 37,000.00 |
| Mar 31, 2024 | 60,000.00 |
| Dec 31, 2023 | 106,000.00 |
| Sep 30, 2023 | 188,000.00 |
| Jun 30, 2023 | -791,000.00 |
| Mar 31, 2023 | -376,000.00 |
| Dec 31, 2022 | -638,000.00 |
| Sep 30, 2022 | -587,000.00 |
| Jun 30, 2022 | -699,000.00 |
| Mar 31, 2022 | -703,000.00 |
| Dec 31, 2021 | -743,000.00 |
| Sep 30, 2021 | -437,000.00 |
| Jun 30, 2021 | -31,000.00 |
| Mar 31, 2021 | 9,000.00 |